SCHEMBL20031175

SCHEMBL20031175

Cc1cc(C2CNC2)ccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UHRF1 Q96T88 1/20 0.43
TLR9 Q9NR96 5/20 0.40
TLR7 Q9NYK1 5/20 0.40
TLR8 Q9NR97 4/20 0.40
CHRNB2 P17787 4/20 0.39
CHRNA4 P43681 4/20 0.39
CHRNB4 P30926 2/20 0.39
CHRNA3 P32297 2/20 0.39
CHRNA1 P02708 1/20 0.39
ESR1 P03372 1/20 0.39
CHRNG P07510 1/20 0.39
CHRNB1 P11230 1/20 0.39
CHRNA5 P30532 1/20 0.39
CHRNA7 P36544 1/20 0.39
HTR3A P46098 1/20 0.39
CHRND Q07001 1/20 0.39
CHRNA2 Q15822 1/20 0.39
IDO1 P14902 1/20 0.39
USP30 Q70CQ3 1/20 0.37
DYRK1A Q13627 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20281434 0.86 TLR9 (0.48) TLR9TLR7TLR8HTR3A
SCHEMBL20281875 0.84 HTR2A (0.48) TLR9TLR7TLR8SLC6A3
SCHEMBL9277352 0.82 IDO1 (0.50) UHRF1TLR9TLR7TLR8IDO1
SCHEMBL5584524 0.81 TLR7 (0.56) TLR9TLR7TLR8
Hydrochloric Acid SCHEMBL1550605 0.80 HTR2C (0.56) TLR9TLR7TLR8
SCHEMBL12093732 0.78 IDO1 (0.45) UHRF1TLR9TLR7TLR8CHRNA7
SCHEMBL12093743 0.78 IDO1 (0.45) UHRF1TLR9TLR7TLR8IDO1
Cyanide SCHEMBL27912025 0.77 IDO1 (0.47) UHRF1TLR9TLR7TLR8IDO1
SCHEMBL22402327 0.77 IDO1 (0.44) UHRF1TLR9TLR7TLR8IDO1
SCHEMBL20757499 0.77 CHRNB2 (0.41) TLR9TLR7TLR8CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11014912-B2 Cyanopyrrolidine derivatives with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-05-25 US disclosed
EP-3519385-B1 CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LTD (GB) 2020-11-18 EP disclosed
WO-2018060689-A1 CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2018-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11014912-B2 Cyanopyrrolidine derivatives with activity as inhibitors of USP30 USP30, USP39, USP28 UHRF1 55/4885TLR9 4791/4885TLR7 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.